Diaceutics uses its data analysis and advisory services to make the development of precision medicines and their related diagnostic tests, more efficient and help pharma companies achieve a better return.
The data itself is a highly valuable asset and significant time and investment would be required for a competitor to develop its own version of the technology and collect the data.
This is a good business. The question is how much should be paid for the shares?
On top of the £17m raised by t...
You are unauthorized to view this page.
